Marker, Cellpoint announce collaboration for cGMP manufacturing of MT-601

Marker Therapeutics (MRKR) announced a collaboration with Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization, for current good manufacturing practice manufacturing, cGMP, of MT-601, Marker’s lead Multi-Antigen Recognizing-T cell therapy. MT-601 is currently being investigated in the Phase 1 APOLLO study in patients with lymphoma who relapsed after anti-CD19 chimeric antigen receptor-T cell therapy or for whom anti-CD19 CAR-T cell therapy is not an option. Marker previously reported a favorable safety profile and objective responses in 7 out of 9 study participants, with 4 participants demonstrating complete response as early as 4 weeks after infusion of MT-601. Under the agreement, Cellipont will provide technology transfer and cGMP manufacturing services to support the scale-up and production of MT-601 for Marker’s APOLLO study. The collaboration between Marker and Cellipont is designed to accelerate clinical supply and lay the foundation for a potential pivotal trial and commercial readiness.